GSA Capital Partners LLP Makes New Investment in Cabaletta Bio, Inc. (NASDAQ:CABA)

GSA Capital Partners LLP acquired a new stake in Cabaletta Bio, Inc. (NASDAQ:CABA) during the 3rd quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund acquired 26,976 shares of the company’s stock, valued at approximately $127,000. GSA Capital Partners LLP owned approximately 0.06% of Cabaletta Bio at the end of the most recent reporting period.

A number of other institutional investors have also modified their holdings of the company. E Fund Management Co. Ltd. lifted its position in Cabaletta Bio by 1,610.1% during the second quarter. E Fund Management Co. Ltd. now owns 286,424 shares of the company’s stock valued at $2,142,000 after buying an additional 269,675 shares in the last quarter. Price T Rowe Associates Inc. MD lifted its holdings in shares of Cabaletta Bio by 16.0% during the 1st quarter. Price T Rowe Associates Inc. MD now owns 612,398 shares of the company’s stock valued at $10,448,000 after acquiring an additional 84,633 shares in the last quarter. Vanguard Group Inc. boosted its position in Cabaletta Bio by 6.8% during the 1st quarter. Vanguard Group Inc. now owns 2,276,222 shares of the company’s stock worth $38,832,000 after purchasing an additional 144,291 shares during the period. Teachers Retirement System of The State of Kentucky purchased a new position in Cabaletta Bio in the first quarter valued at about $305,000. Finally, Victory Capital Management Inc. raised its position in Cabaletta Bio by 70.7% in the second quarter. Victory Capital Management Inc. now owns 634,217 shares of the company’s stock valued at $4,744,000 after purchasing an additional 262,594 shares during the period.

Cabaletta Bio Stock Up 22.5 %

Shares of Cabaletta Bio stock opened at $2.29 on Tuesday. The business has a 50-day moving average price of $4.00 and a 200 day moving average price of $6.43. Cabaletta Bio, Inc. has a fifty-two week low of $1.76 and a fifty-two week high of $26.35. The firm has a market cap of $111.94 million, a P/E ratio of -1.07 and a beta of 2.42.

Wall Street Analyst Weigh In

CABA has been the subject of a number of recent research reports. William Blair reiterated an “outperform” rating on shares of Cabaletta Bio in a research note on Monday, November 18th. Evercore ISI lowered their price objective on shares of Cabaletta Bio from $25.00 to $15.00 and set an “outperform” rating for the company in a research report on Monday, August 12th. UBS Group initiated coverage on shares of Cabaletta Bio in a research note on Thursday, October 10th. They issued a “buy” rating and a $10.00 target price for the company. Wells Fargo & Company dropped their price target on shares of Cabaletta Bio from $20.00 to $12.00 and set an “overweight” rating on the stock in a research note on Friday, November 15th. Finally, HC Wainwright reissued a “buy” rating and issued a $25.00 price objective on shares of Cabaletta Bio in a research report on Friday, November 15th. Ten analysts have rated the stock with a buy rating, According to MarketBeat, the company has a consensus rating of “Buy” and a consensus price target of $27.30.

Cabaletta Bio Profile

Cabaletta Bio, Inc, a clinical-stage biotechnology company, focuses on the discovery and development of engineered T cell therapies for patients with B cell-mediated autoimmune diseases. The company's lead product candidate is CABA-201, a fully human anti-CD19 binder for the treatment of Phase 1/2 clinical trials in dermatomyositis, anti-synthetase syndrome, immune-mediated necrotizing myopathy, lupus nephritis, non-renal systemic lupus erythematosus, systemic sclerosis, and generalized myasthenia gravis.